Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Valneva ( (VALN) ).
Valneva announced that its management team will engage with investors at the J.P. Morgan Healthcare Conference, where they will discuss the company’s commercial vaccine portfolio and clinical development pipeline. Expectations for 2024 revenue are set between €160-€170 million, with significant attention on the pivotal data for its Lyme disease vaccine. This engagement is part of Valneva’s strategy to bolster its market presence and investor relations, potentially impacting its operations and positioning in the vaccine industry.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing either first-, best- or only-in-class vaccine solutions, with a strong track record of advancing vaccines from early R&D to approvals. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and is advancing a pipeline featuring the only Lyme disease vaccine candidate in advanced clinical development, in partnership with Pfizer, as well as candidates against Shigella and Zika virus.
YTD Price Performance: -0.64%
Average Trading Volume: 38,511
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $385.4M
For an in-depth examination of VALN stock, go to TipRanks’ Stock Analysis page.
